All Stories

  1. Pre-transplant HbA1c and BMI are associated with long-term survival after lung transplantation
  2. Bronchoalveolar lavage for supporting acute cellular rejection in lung transplant recipients: A retrospective analysis
  3. Hypophosphatemia after intravenous ferric carboxymaltose in lung transplant recipients
  4. A Perspective Summary of the ISHLT Consensus Statement on Acute Lung Allograft Dysfunction (ALAD)
  5. ISHLT Consensus Statement on Acute Lung Allograft Dysfunction (ALAD): Definition, Etiology, Diagnostic and Therapeutic Approaches, and Research Priorities
  6. Cystic fibrosis is associated with the greatest long-term survival after lung transplantation: 30 years of the Zurich experience
  7. Pharmacological pitfalls in inpatient lung transplant care and management of medication risks
  8. Donor-recipient sex differences: Implications for immunologic outcomes but no impact on survival after lung transplantation
  9. Correlation between acute cellular rejection detected with cryobiopsy and elevated donor-derived cell-free DNA in lung transplant recipients
  10. Management of microaspiration and gastrointestinal dysfunction after lung transplantation: A narrative review
  11. Tacrolimus overdosing in lung transplant recipients: clinical manifestations and management
  12. Coronavirus infection and chronic lung allograft dysfunction: a retrospective cohort study
  13. EPS4.03Improved liver stiffness after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A 7-year cohort study
  14. Transbronchial cryobiopsy alone versus combined with traditional forceps biopsy for acute cellular rejection in lung transplant recipients. A diagnostic randomized trial
  15. Neutrophil-to-lymphocyte ratio as a prognostic marker for lung cancer in combined pulmonary fibrosis and emphysema patients
  16. Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function
  17. Clinical characteristics and outcomes in patients with Anti-MDA5 positive interstitial lung disease: A case series from a lung transplant center
  18. Combined pulmonary fibrosis and emphysema and lung transplantation: current evidence and future directions
  19. Transbronchial forceps- and cryobiopsy for detecting acute cellular rejection in lung transplant recipients: A randomised trial
  20. Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
  21. 263.11: ACR detected with cryobiopsy in lung transplant recipients is not associated with elevated dd-cfDNA.
  22. P.041: Switching from ciclosporin to tacrolimus as de novo calcineurin inhibitor in lung transplantation: First results of a multidisciplinary quality assurance project.
  23. Blickdiagnose für Fortgeschrittene
  24. Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study
  25. Early extracorporeal photopheresis treatment is associated with better survival in patients with chronic or recurrent acute lung allograft dysfunction
  26. mTOR inhibitors after lung transplantation: a real-life experience
  27. Association between anion gap and the 30-day mortality of patients with ventilator-associated pneumonia: a study of the MIMIC-III database
  28. Controlled Donation After Circulatory Death Lung Transplantation in University Hospital Zurich: 10-years' Experience
  29. Indirect Recognition HLA Score as a Predictor of CLAD In Lung Transplant
  30. Pretransplant management of coexisting diseases
  31. Frailty as a Prognostic Indicator in Lung Transplantation: A Comprehensive Analysis
  32. Impact of SARS-CoV-2-Related Hygiene Measures on Community-Acquired Respiratory Virus Infections in Lung Transplant Recipients in Switzerland
  33. Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis
  34. Multimodal Remote Home Monitoring of Lung Transplant Recipients during COVID-19 Vaccinations: Usability Pilot Study of the COVIDA Desk Incorporating Wearable Devices
  35. Adaptive Immunosuppression in Lung Transplant Recipients Applying Complementary Biomarkers: The Zurich Protocol
  36. COVID-Related Chronic Allograft Dysfunction in Lung Transplant Recipients: Long-Term Follow-up Results from Infections Occurring in the Pre-vaccination Era
  37. Influence of mycophenolate mofetil dosage and plasma levels on the occurrence of chronic lung allograft dysfunction in lung transplants.
  38. Influence of mycophenolate mofetil dosage and plasma levels on the occurrence of chronic lung allograft dysfunction in lung transplants: a retrospective cohort analysis
  39. COVID-19-Associated Lung Fibrosis: Two Pathways and Two Phenotypes, Lung Transplantation, and Antifibrotics
  40. Transbronchial Cryobiopsy Compared to Forceps Biopsy for Diagnosis of Acute Cellular Rejection in Lung Transplants: Analysis of 63 Consecutive Procedures
  41. ePS4.10 Evaluation of possible adverse events in relationship to the SARS-CoV-2 vaccination in cystic fibrosis patients with or without lung transplantation: a retrospective single-centre case series
  42. COVID-19-related end stage lung disease: two distinct phenotypes
  43. Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19
  44. Transbronchial Cryobiopsy Compared to Forceps Biopsy for Diagnosis of Acute Cellular Rejection in Lung Transplant Recipients
  45. Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management
  46. Cyclosporine A and COVID-19 – The COQUIMA cohort
  47. P137 COVID-19 in cystic fibrosis patients with and without lung transplantation: the Zurich cohort
  48. Clinical Aspects of COVID-19 in Patients with Solid Organ Transplantation: A Systematic Review
  49. COVID-19 in solid organ transplant recipients
  50. Transplant Drugs against SARS, MERS and COVID-19
  51. Vaping-assoziierte Lungenerkrankung «VAPI»
  52. Work Reintegration after Lung Transplantation: A Complex and Multifaceted Topic
  53. Calcineurin Inhibitors and COVID-19
  54. Electronic cigarettes and vaping associated pulmonary illness (VAPI): A narrative review
  55. Calcineurin inhibitors revisited: A new paradigm for COVID-19?
  56. Suggested management of e-cigarette or vaping product use associated lung injury (EVALI)
  57. SARS-CoV-2 and Norovirus Co-Infection after Lung Transplantation
  58. COVID-19 in Patients with Solid Organ Transplantation: A Systematic Review
  59. Malaria-associated pulmonary edema
  60. Rapid review: sinonasal surgery vs. medical therapy for asthma in patients with chronic rhinosinusitis with or without nasal polyps
  61. Accuracy of symptoms, signs, and C-reactive protein for early chronic obstructive pulmonary disease
  62. Large-cell neuroendocrine carcinoma (LCNC) of the lung: a dilemma
  63. Reply to Filosso
  64. Update in Pulmonary Carcinoid Tumors: A Review Article
  65. Pulmonary large-cell neuroendocrine carcinoma (LCNEC)
  66. Primitive neuroectodermal tumor: Report of two cases and review of the literature
  67. Neural Cell Adhesion Molecule Expression
  68. Neo-adjuvant chemotherapy followed by surgery and/or radiotherapy in patients with stage IIIB non-small cell lung cancer (NSCLC), preliminary data
  69. Surgery for combined type small cell lung carcinoma
  70. Antiarrhythmic Effects of Increasing the Daily Intake of Magnesium and Potassium in Patients With Frequent Ventricular Arrhythmias fn1fn1This study was supported by Trommsdorff GmbH and Company, Alsdorf, Germany and Hexal AG, Holzkirchen, Germany.
  71. Detection of flow limitation during tidal breathing by the interruptor technique